Imp points:-
- CSD approval received in March’24
- Paramil approval in Aug’24.
Basically a major distribution channel was absent in FY24 and yet Indri has done around 85k cases for the full year. With both of these approvals in place and Q3FY25 still some time away, we can hope for good volume growth.
Let’s see.
Subscribe To Our Free Newsletter |